Jeanine Harrigan
About Jeanine Harrigan
Jeanine Harrigan is the Director of Drug Discovery at BenevolentAI, with extensive experience in drug discovery and development, particularly in oncology.
Current Position at BenevolentAI
Jeanine Harrigan currently holds the position of Director Drug Discovery at BenevolentAI. She joined the company in January 2020 and is responsible for leading drug discovery initiatives. With a focus on the field of oncology, she leverages her extensive academic and industry experience to drive innovative research and development projects aimed at identifying new therapeutic targets.
Previous Roles at MISSION Therapeutics
Jeanine Harrigan has an extensive tenure at MISSION Therapeutics, where she held several key roles over a seven-year period. Her positions included Senior Scientist (2012-2013), Principal Scientist (2013-2016), and VP Discovery Biology (2016-2019). Throughout her time at the company, she played a pivotal role in leading discovery biology initiatives and contributed significantly to the company’s research and development efforts.
Background in Academia
Before transitioning to the biotechnology sector, Jeanine Harrigan had a robust academic career. She worked as a Postdoctoral Fellow at the University of Cambridge from 2005 to 2011 and prior to that, at the National Institute on Aging (NIA) from 2001 to 2005. Her academic background has provided her with a strong foundation in pharmacology and toxicology, which she continues to apply in her industry roles.
Educational Credentials
Jeanine Harrigan earned her PhD in Pharmacology and Toxicology from the University at Buffalo, where she studied from 1996 to 2001. She also holds a BS in Nutrition Science from Syracuse University, completed between 1989 and 1993. Her education has laid a solid groundwork for her career in pharmacology, toxicology, and drug discovery.
Experience in Drug Discovery and Development
Jeanine Harrigan has a well-documented history in the field of drug discovery and development, with a particular focus on oncology. Her expertise spans both academic and industry settings, where she has led numerous research projects aimed at advancing the understanding of disease mechanisms. She also has a strong publication record in peer-reviewed journals and has been instrumental in mentoring junior scientists and researchers.